Oncology

Key steps forward in disease control in Sub-Saharan Africa

The author, Shyama Ghosh, recently completed a detailed study of the disease landscape in Sub-Saharan Africa. Titled “Disease control in Sub-Saharan Africa: Are we doing enough?”, the following is an excerpt.   Amid the many challenges facing Sub-Saharan Africa (SSA), there are signs of progress, as well. The RB Group, in India, noting the growth […]

Opioid Epidemic Spawns Flurry of PBM Programs to Address Abuse

Express Scripts, other major PBMs tighten controls on opioids Abuse and overuse of opioids continues to be a hot topic as lawmakers and healthcare industry stakeholders take aim at programs to combat the epidemic. According to the Centers for Disease Control and Prevention, most overdose deaths involve an opioid and deaths from prescription opioids have […]

CAR T-cell gene therapies enter the U.S. market

Ground-breaking anti-cancer immunotherapy Novartis and the University of Pennsylvania’s anti-cancer chimeric antigen receptor (CAR) T-cell therapy Kymriah has become the first ever gene-modified therapy approved in the U.S. The therapy takes the patient’s own T cells, engineers them to express a receptor that binds to the B-cell blood cancer marker CD19, and then re-infuses them […]

The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Poly ADP-ribose polymerase (PARP) inhibitors have created much excitement in the medical community since the demonstration in 2005 of the extreme sensitivity […]

Lung cancer – continued progress in personalized care

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.

Checkpoint inhibitors: a cutting edge in oncology

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.

Direct-to-consumer: New avenue for PBMs could provide political shelter

Departing from their traditional role working for payers as third-party administrators of prescription drug coverage, two of the largest pharmacy benefit managers are taking a direct-to-consumer approach through drug discount programs.   The discount cards (also known as consumer cards, point-of-sales cards, or 100 percent copay cards) bypass the payers that PBMs typically serve, disrupting […]

NGS, maybe, sort of, sometimes clinic ready

Detailed genomic profiling is a sine qua non of precision medicine, and at tertiary cancer centers, the comprehensive profiling of tumors and matched germline DNA is becoming ever more routine.

Hot Topics at ASCO 2017 – Part 2

ASCO 2017 is nearly upon us, so here is the second of our blogs covering key data that will be released, this time in the latter part of the conference. As before, don’t forget to use our handy guides below on how to get around to these presentations while you’re there.   Results of adjuvant […]